TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 75 filers reported holding TARSUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 4.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,190,057 | +11.2% | 2,880,701 | +13.1% | 1.08% | +23.1% |
| Q2 2023 | $46,044,619 | +43.8% | 2,548,125 | 0.0% | 0.88% | +31.5% |
| Q1 2023 | $32,029,931 | -14.3% | 2,548,125 | 0.0% | 0.67% | -12.6% |
| Q4 2022 | $37,355,513 | +7.8% | 2,548,125 | +25.9% | 0.76% | -4.5% |
| Q3 2022 | $34,637,000 | +17.8% | 2,023,179 | +0.5% | 0.80% | +5.1% |
| Q2 2022 | $29,399,000 | -13.2% | 2,013,601 | 0.0% | 0.76% | +8.4% |
| Q1 2022 | $33,869,000 | -25.2% | 2,013,601 | 0.0% | 0.70% | +5.9% |
| Q4 2021 | $45,306,000 | +4.4% | 2,013,601 | 0.0% | 0.66% | +1.2% |
| Q3 2021 | $43,393,000 | -25.6% | 2,013,601 | 0.0% | 0.65% | -25.8% |
| Q2 2021 | $58,354,000 | -26.2% | 2,013,601 | -18.3% | 0.88% | -28.7% |
| Q1 2021 | $79,091,000 | -20.1% | 2,463,601 | 0.0% | 1.24% | -25.6% |
| Q4 2020 | $98,987,000 | – | 2,463,601 | – | 1.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,084,370 | $30,432,000 | 4.62% |
| Vivo Capital, LLC | 2,312,368 | $33,761,000 | 3.39% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $26,098,000 | 2.46% |
| Cormorant Asset Management, LP | 1,875,000 | $27,375,000 | 2.07% |
| Sands Capital Ventures, LLC | 260,000 | $3,796,000 | 1.04% |
| Ghost Tree Capital, LLC | 120,000 | $1,752,000 | 0.91% |
| RTW INVESTMENTS, LP | 2,013,601 | $29,399,000 | 0.76% |
| COWEN AND COMPANY, LLC | 534,524 | $7,804,000 | 0.75% |
| Perceptive Advisors | 1,296,416 | $18,927,000 | 0.59% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $19,334,000 | 0.40% |